BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38575457)

  • 1. Advances in the Imaging of Esophageal and Gastroesophageal Junction Malignancies.
    Ruby L; Jayaprakasam VS; Fernandes MC; Paroder V
    Hematol Oncol Clin North Am; 2024 Jun; 38(3):711-730. PubMed ID: 38575457
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Linder G; Korsavidou-Hult N; Bjerner T; Ahlström H; Hedberg J
    Clin Radiol; 2019 Sep; 74(9):718-725. PubMed ID: 31221468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.
    Smyth EC; Shah MA
    World J Gastroenterol; 2011 Dec; 17(46):5059-74. PubMed ID: 22171140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using
    Ma CL; Li XD; Sun XR; Zhao DB; Yuan YP; Yu YH
    J Cancer Res Ther; 2018; 14(4):896-901. PubMed ID: 29970673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma - review.
    Zemanová M; Obermannová R; Haruštiak T
    Klin Onkol; 2021; 34(2):113-119. PubMed ID: 33906359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State-of-the-art imaging in oesophago-gastric cancer.
    Withey SJ; Goh V; Foley KG
    Br J Radiol; 2022 Sep; 95(1137):20220410. PubMed ID: 35671095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a role for PET/CT with esophagogastric junction adenocarcinoma?
    Fuster D; Mayoral M; Rubello D; Pineda E; Fernández-Esparrach G; Pagès M; Colletti PM; Pons F
    Clin Nucl Med; 2015 Mar; 40(3):e201-7. PubMed ID: 25546207
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Lehmann K; Eshmuminov D; Bauerfeind P; Gubler C; Veit-Haibach P; Weber A; Abdul-Rahman H; Fischer M; Reiner C; Schneider PM
    Eur J Surg Oncol; 2017 Jan; 43(1):196-202. PubMed ID: 27692533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation between molecular pathological profiles and metabolic parameters of
    Song J; Li Z; Chen P; Zhou N; Zhang Y; Yang Z; Wang X
    Abdom Radiol (NY); 2020 Feb; 45(2):312-321. PubMed ID: 31111196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography in gastric and esophageal cancer.
    Flamen P
    Curr Opin Oncol; 2004 Jul; 16(4):359-63. PubMed ID: 15187891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic tumor volume provides complementary prognostic information to EUS staging in esophageal and junctional cancer.
    Malik V; Johnston C; O'Toole D; Lucey J; O'Farrell N; Claxton Z; Reynolds JV
    Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27862622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer.
    Goel R; Subramaniam RM; Wachsmann JW
    PET Clin; 2017 Oct; 12(4):373-391. PubMed ID: 28867110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of regular endosonography and [18F]fluorodeoxyglucose PET-CT after surgery for gastro-oesophageal junction, stomach or pancreatic cancer.
    Bjerring OS; Hess S; Petersen H; Fristrup CW; Lundell L; Mortensen MB
    BJS Open; 2021 Mar; 5(2):. PubMed ID: 33688946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma.
    Papaxoinis G; Weaver JMJ; Khoja L; Patrao A; Stamatopoulou S; Alchawaf A; Owen-Holt V; Germetaki T; Kordatou Z; Mansoor W
    Acta Oncol; 2017 Sep; 56(9):1224-1232. PubMed ID: 28524708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies].
    Yun HW; Shim KN
    Korean J Gastroenterol; 2013 Jun; 61(6):303-6. PubMed ID: 23877209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy.
    Abdelhakeem A; Patnana M; Wang X; Rogers JE; Murphy MB; Sagebiel T; Ikoma N; Badgwell BD; Trail A; Estrella JS; Lu Y; Devine C; Ajani JA
    Oncology; 2021; 99(10):659-664. PubMed ID: 34352788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy.
    Lerut T; Flamen P; Ectors N; Van Cutsem E; Peeters M; Hiele M; De Wever W; Coosemans W; Decker G; De Leyn P; Deneffe G; Van Raemdonck D; Mortelmans L
    Ann Surg; 2000 Dec; 232(6):743-52. PubMed ID: 11088069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer.
    Paudel N; Kunz PL; Poultsides GA; Koong AC; Chang DT
    Pract Radiat Oncol; 2014; 4(6):368-71. PubMed ID: 25407856
    [No Abstract]   [Full Text] [Related]  

  • 19. The lung cancers: staging and response, CT,
    Owens C; Hindocha S; Lee R; Millard T; Sharma B
    Br J Radiol; 2023 Aug; 96(1148):20220339. PubMed ID: 37097296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods.
    Kroep JR; Van Groeningen CJ; Cuesta MA; Craanen ME; Hoekstra OS; Comans EF; Bloemena E; Hoekstra CJ; Golding RP; Twisk JW; Peters GJ; Pinedo HM; Lammertsma AA
    Mol Imaging Biol; 2003; 5(5):337-46. PubMed ID: 14630513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.